M Chen1, Z D Yang, K M Smith, J D Carter, J L Nadler. 1. Department of Medicine, Division of Endocrinology and Metabolism, School of Medicine, University of Virginia, PO Box 801405, Charlottesville, VA, 22908-1405, USA.
Abstract
AIMS/HYPOTHESIS: Beta cell inflammation and cytokine-induced toxicity are central to autoimmune diabetes development. Lipid mediators generated upon lipoxygenase (LO) activation can participate in inflammatory pathways. 12LO-deficient mice are resistant to streptozotocin-induced diabetes. This study sought to characterise the cellular processes involving 12LO-activation lipid inflammatory mediator production in cytokine-treated pancreatic beta cells. METHODS: Islets and beta cell lines were treated with a combination of IL-1beta, IFN-gamma and TNF-alpha, or the 12LO product 12(S)-hydroxyeicosatetraenoic acid (HETE). Insulin secretion was measured using an enzyme immunoassay, and cell viability was evaluated using an in situ terminal deoxynucleotidyl transferase-mediated dUTP nick-end labelling assay. 12LO activity was evaluated and 12LO protein levels were determined using immunoblotting with a selective leucocyte type 12LO antibody. Cellular localisation of 12LO was evaluated using immunocytochemistry. RESULTS: Basal expression of leucocyte type 12LO protein was found in human and mouse islets and in several rodent beta cell lines. In mouse beta-TC3 cells, and in human islets, cytokines induced release of 12-HETE within 30 min. Cytokine addition also induced a rapid translocation of 12LO protein from the cytosol to the nucleus of beta-TC3 cells as shown by subcellular fractionation and immunostaining. Cytokine-induced cell death and inhibition of insulin secretion were partially reversed by baicalein, a 12LO inhibitor. 12(S)-HETE inhibited beta-TC3 cell insulin release in a time- and concentration-dependent manner. Incubating beta-TC3 cells with 100 nmol/l of 12(S)-HETE resulted in a 57% reduction in basal insulin release (6 h), and a 17% increase in cell death (18 h) as compared with untreated cells. 12(S)-HETE activated the stress-activated protein kinase c-Jun N-terminal kinase and p38 within 15 min, as judged by increased kinase protein phosphorylation. CONCLUSIONS/ INTERPRETATION: The data suggest that inflammatory cytokines rapidly activate 12LO and show for the first time that cytokines induce 12LO translocation. The effects of 12-HETE on insulin secretion, cytotoxicity and kinase activation were similar to the effects seen with cytokines. The results provide mechanistic information of cytokine-induced toxic effects on pancreatic beta cells and support the hypothesis that blocking 12LO activation could provide a new therapeutic way to protect pancreatic beta cells from autoimmune injury.
AIMS/HYPOTHESIS: Beta cell inflammation and cytokine-induced toxicity are central to autoimmune diabetes development. Lipid mediators generated upon lipoxygenase (LO) activation can participate in inflammatory pathways. 12LO-deficient mice are resistant to streptozotocin-induced diabetes. This study sought to characterise the cellular processes involving 12LO-activation lipid inflammatory mediator production in cytokine-treated pancreatic beta cells. METHODS: Islets and beta cell lines were treated with a combination of IL-1beta, IFN-gamma and TNF-alpha, or the 12LO product 12(S)-hydroxyeicosatetraenoic acid (HETE). Insulin secretion was measured using an enzyme immunoassay, and cell viability was evaluated using an in situ terminal deoxynucleotidyl transferase-mediated dUTP nick-end labelling assay. 12LO activity was evaluated and 12LO protein levels were determined using immunoblotting with a selective leucocyte type 12LO antibody. Cellular localisation of 12LO was evaluated using immunocytochemistry. RESULTS: Basal expression of leucocyte type 12LO protein was found in human and mouse islets and in several rodent beta cell lines. In mouse beta-TC3 cells, and in human islets, cytokines induced release of 12-HETE within 30 min. Cytokine addition also induced a rapid translocation of 12LO protein from the cytosol to the nucleus of beta-TC3 cells as shown by subcellular fractionation and immunostaining. Cytokine-induced cell death and inhibition of insulin secretion were partially reversed by baicalein, a 12LO inhibitor. 12(S)-HETE inhibited beta-TC3 cell insulin release in a time- and concentration-dependent manner. Incubating beta-TC3 cells with 100 nmol/l of 12(S)-HETE resulted in a 57% reduction in basal insulin release (6 h), and a 17% increase in cell death (18 h) as compared with untreated cells. 12(S)-HETE activated the stress-activated protein kinase c-Jun N-terminal kinase and p38 within 15 min, as judged by increased kinase protein phosphorylation. CONCLUSIONS/ INTERPRETATION: The data suggest that inflammatory cytokines rapidly activate 12LO and show for the first time that cytokines induce 12LO translocation. The effects of 12-HETE on insulin secretion, cytotoxicity and kinase activation were similar to the effects seen with cytokines. The results provide mechanistic information of cytokine-induced toxic effects on pancreatic beta cells and support the hypothesis that blocking 12LO activation could provide a new therapeutic way to protect pancreatic beta cells from autoimmune injury.
Authors: M K Patricia; J A Kim; C M Harper; P T Shih; J A Berliner; R Natarajan; J L Nadler; C C Hedrick Journal: Arterioscler Thromb Vasc Biol Date: 1999-11 Impact factor: 8.311
Authors: Roman Stavniichuk; Viktor R Drel; Hanna Shevalye; Yury Maksimchyk; Tamara M Kuchmerovska; Jerry L Nadler; Irina G Obrosova Journal: Exp Neurol Date: 2011-04-16 Impact factor: 5.330
Authors: Anca D Dobrian; David C Lieb; Banumathi K Cole; David A Taylor-Fishwick; Swarup K Chakrabarti; Jerry L Nadler Journal: Prog Lipid Res Date: 2010-10-21 Impact factor: 16.195
Authors: William H Witola; Susan Ruosu Liu; Alexandre Montpetit; Ruth Welti; Magali Hypolite; Mary Roth; Ying Zhou; Ernest Mui; Marie-France Cesbron-Delauw; Gilbert J Fournie; Pierre Cavailles; Cordelia Bisanz; Kenneth Boyer; Shawn Withers; A Gwendolyn Noble; Charles N Swisher; Peter T Heydemann; Peter Rabiah; Stephen P Muench; Rima McLeod Journal: Infect Immun Date: 2014-03-31 Impact factor: 3.441
Authors: Swarup K Chakrabarti; Yeshao Wen; Anca D Dobrian; Banumathi K Cole; Qian Ma; Hong Pei; Michael D Williams; Melissa H Bevard; George E Vandenhoff; Susanna R Keller; Jiali Gu; Jerry L Nadler Journal: Am J Physiol Endocrinol Metab Date: 2010-10-26 Impact factor: 4.310
Authors: Diane K Luci; J Brian Jameson; Adam Yasgar; Giovanni Diaz; Netra Joshi; Auric Kantz; Kate Markham; Steve Perry; Norine Kuhn; Jennifer Yeung; Edward H Kerns; Lena Schultz; Michael Holinstat; Jerry L Nadler; David A Taylor-Fishwick; Ajit Jadhav; Anton Simeonov; Theodore R Holman; David J Maloney Journal: J Med Chem Date: 2014-01-06 Impact factor: 7.446
Authors: Craig S Nunemaker; Meng Chen; Hong Pei; Sarah D Kimble; Susanna R Keller; Jeffrey D Carter; Zandong Yang; Kellie M Smith; Runpei Wu; Melissa H Bevard; James C Garmey; Jerry L Nadler Journal: Am J Physiol Endocrinol Metab Date: 2008-09-09 Impact factor: 4.310
Authors: K Ma; C S Nunemaker; R Wu; S K Chakrabarti; D A Taylor-Fishwick; J L Nadler Journal: J Clin Endocrinol Metab Date: 2010-01-20 Impact factor: 5.958